Vigil Neuroscience, Inc. has announced its financial results for Q1 2025 and provided updates on its clinical trials. The company is on track to report the final analysis from its Phase 2 IGNITE trial ...

WATERTOWN, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...

JUPITER, FL, UNITED STATES, February 25, 2026 /EINPresswire.com/ — Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage ...

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Tortugas Neuroscience (“Tortugas”), a neurology-focused biotech company developing novel medicines with derisked mechanisms of actions, for large and well-defined ...

– Convergent clinical and preclinical evidence supports the mechanistic link between ALTO-300 and the biomarker, a measure of greater EEG irregularity, being used for patient selection – – Completed ...

The collaboration expands Precision's clinical research network, deepening investigation into AI-driven neural cursor control and neuroprostheticsNEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Precision ...

ANPD001 was well tolerated with no major safety issues in low-dose cohort Patients showed early improvements in patient-reported and clinician-reported outcomes Detailed Phase 1/2a trial data will be ...

Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD ...

Axon Neuroscience’s active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer’s disease phase 2 clinical trial (supported by a USD ...